Audentes Therapeutics Inc. (BOLD)’s Financial Results Comparing With Fortress Biotech Inc. (NASDAQ:FBIO)

Audentes Therapeutics Inc. (NASDAQ:BOLD) and Fortress Biotech Inc. (NASDAQ:FBIO) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Audentes Therapeutics Inc. N/A 0.00 152.64M -3.79 0.00
Fortress Biotech Inc. 27.46M 4.02 52.68M -1.68 0.00

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 demonstrates the return on assets, return on equity and net margins of Audentes Therapeutics Inc. and Fortress Biotech Inc.

Net Margins Return on Equity Return on Assets
Audentes Therapeutics Inc. 0.00% -40.8% -37.4%
Fortress Biotech Inc. -191.84% 0% 0%

Liquidity

The Current Ratio and Quick Ratio of Audentes Therapeutics Inc. are 14.3 and 14.3 respectively. Its competitor Fortress Biotech Inc.’s Current Ratio is 2 and its Quick Ratio is 2. Audentes Therapeutics Inc. can pay off short and long-term obligations better than Fortress Biotech Inc.

Analyst Recommendations

In next table is given Audentes Therapeutics Inc. and Fortress Biotech Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Audentes Therapeutics Inc. 0 0 1 3.00
Fortress Biotech Inc. 0 0 1 3.00

Audentes Therapeutics Inc. has a consensus target price of $48, and a 26.48% upside potential. Competitively Fortress Biotech Inc. has a consensus target price of $11, with potential upside of 550.89%. The results from earlier shows that analysts belief suggest that Fortress Biotech Inc. seems more appealing than Audentes Therapeutics Inc.

Insider and Institutional Ownership

Institutional investors owned 0% of Audentes Therapeutics Inc. shares and 11.3% of Fortress Biotech Inc. shares. Audentes Therapeutics Inc.’s share owned by insiders are 1.3%. Comparatively, 32.5% are Fortress Biotech Inc.’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Audentes Therapeutics Inc. 1.16% -5.46% 61.44% 59.29% 9.29% 79.32%
Fortress Biotech Inc. 5.95% 14.84% -18.35% 61.82% -50.83% 106.98%

For the past year Audentes Therapeutics Inc.’s stock price has smaller growth than Fortress Biotech Inc.

Summary

Fortress Biotech Inc. beats Audentes Therapeutics Inc. on 8 of the 10 factors.

Audentes Therapeutics, Inc., a biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects in the United States. The company is developing AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT982 for the treatment of pompe disease; and AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. Audentes Therapeutics, Inc. has a collaboration with the University of Pennsylvania for the treatment of Crigler-Najjar. The company was founded in 2012 and is headquartered in San Francisco, California.

Fortress Biotech, Inc., a biopharmaceutical company, engages in dermatology product sales, pharmaceutical, and biotechnology businesses in the United States. The company offers CNDO-109, a lysate that activates donor natural killer cells to treat cancer-related and other conditions; tramadol HCl, an intravenous formulation for moderate to moderately severe post-operative pain; CAEL-101 for AL amyloidosis; and CEVA101, which is in Phase II clinical study for severe traumatic brain injury in pediatric patients and adults. It also provides novel, non-chemotherapy, and immune-enhanced combination treatments for patients with solid tumor cancers; Uracil Topical Cream that is in Phase II to treat and prevent hand-foot syndrome; candidate CUTX-101, a copper histidinate injection for Menkes disease and related copper transport disorders; and novel agents for rare, neglected, or orphan disorders. In addition, the company is developing novel immunotherapies for the prevention and treatment of cancer and infectious disease; Targadox for severe acne; Luxamend, a wound cream; Ceracade, a skin emulsion; Chimeric Antigen Receptor that is in Phase I clinical trial for acute myeloid leukemia and brain cancer; and MB-101, which is in Phase I clinical trial for glioblastoma. Further, it offers full service retail brokerage and wealth management services to high net worth individual and institutional clients; investment banking, merger and acquisition, and advisory services to micro, small, and mid-cap high growth companies; trades in securities, such as making markets in micro and small-cap NASDAQ, and other exchange listed stocks; liquidity services in the United States Treasury marketplace; and tax preparation, fixed insurance sales, and licensed mortgage brokerage services. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was founded in 2006 and is based in New York, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.